Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron's COVID-19 antibody drug may be less effective against Omicron

11/30/2021 | 06:24am EST

Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.

Global markets tumbled after comments from Moderna's chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.

Based on its study of Omicron's individual mutations, "there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity", Regeneron said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.

The company said it was doing further study to quantify the potential impact using the variant's genetic sequence.

One of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.

"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals."

Eli Lilly and Co, which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.

Regeneron shares fell about 3% in morning trading, while those of Lilly shed 2.5%.

Rival Vir Biotechnology Inc said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.

The company is "working to confirm this in the lab as a matter of urgency", it added.

Gilead Inc said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron

The U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.

(Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta, Sriraj Kalluvila and Anil D'Silva)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. -2.18% 67.34 Delayed Quote.-7.26%
MODERNA, INC. 1.59% 154.96 Delayed Quote.-38.99%
REGENERON PHARMACEUTICALS 0.34% 605.25 Delayed Quote.-4.16%
VIR BIOTECHNOLOGY, INC. 3.03% 32.31 Delayed Quote.-22.83%
All news about REGENERON PHARMACEUTICALS
01/25GLOBAL MARKETS LIVE : Credit Suisse, Unilever, Nvidia, Tesla, American Express...
01/25WALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
01/25MARKETSCREENER’S WORLD PRESS REVIEW : January 25, 2022
01/24REGENERON PHARMACEUTICALS : U.S. Food and Drug Administration Revises Emergency Use Author..
PU
01/24U.S. FDA limits use of Regeneron, Lilly COVID-19 antibody treatments
RE
01/24U.S. FDA to restrict use of Regeneron, Lilly COVID antibody drugs - WaPo
RE
01/24FDA to Restrict Monoclonal Antibodies Manufactured by Eli Lilly, Regeneron Pharmaceutic..
MT
01/24UK to begin testing Merck's COVID pill for hospitalized patients
RE
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Regeneron - FORTY ACCOMPLISHED YOUNG SCIENTISTS NAMED FINALISTS IN THE 2022 REGENERON S..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 548 M - -
Net income 2021 7 971 M - -
Net cash 2021 4 180 M - -
P/E ratio 2021 8,59x
Yield 2021 -
Capitalization 63 282 M 63 282 M -
EV / Sales 2021 3,80x
EV / Sales 2022 4,20x
Nbr of Employees 9 766
Free-Float 81,7%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 605,25 $
Average target price 697,73 $
Spread / Average Target 15,3%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS-4.16%63 282
GILEAD SCIENCES, INC.-7.26%84 470
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812
BEIGENE, LTD.-17.13%23 067